Independent
Tenure on this board
1.8 yrs
Meeting calendar
BCAX · Annual meeting · Tuesday, June 9, 2026
Bicara Therapeutics Inc
2 nominees · 2 ballot items.
Election of two Class II directors (Christopher Bowden, M.D. and Carolyn Ng, Ph.D.) and ratification of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Market cap
$1.8B
1Y TSR
+157.4%
Board grade
C
Record date
Apr 15, 2026
Filing
DEF 14A
Meeting concluded · Jun 9, 2026
Follow how the vote landed and what changed on Bicara Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class II Directors (Christopher Bowden, M.D. and Carolyn Ng, Ph.D.
ManagementBoard: FORElect two Class II directors to the board to serve three-year terms expiring in 2029 (nominees: Christopher Bowden, M.D. and Carolyn Ng, Ph.D.).
- 2
Ratification of the Appointment of KPMG LLP as Independent Registered Public Accounting Firm for Fiscal Year Ending December 31, 2026
ManagementBoard: FORRatify the audit committee’s appointment of KPMG LLP as Bicara Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
1.8 yrs
Also a director at
Odyssey Therapeutics Inc (ODTX)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 11.0% | 7,255,993 | $144M |
| 2 | T. Rowe Price Investment Management, Inc. | 10.1% | 6,605,780 | $131M |
| 3 | Siren, L.L.C. | 8.8% | 5,802,970 | $115M |
| 4 | Vestal Point Capital, LP | 8.3% | 5,425,000 | $108M |
| 5 | Deep Track Capital, LP | 6.2% | 4,062,500 | $81M |
| 6 | JANUS HENDERSON GROUP PLC | 5.1% | 3,326,918 | $66M |
| 7 | Red Tree Management, LLC | 4.8% | 3,170,509 | $63M |
| 8 | TPG GP A, LLC | 4.6% | 3,010,425 | $60M |
| 9 | Omega Fund Management, LLC | 3.6% | 2,392,150 | $48M |
| 10 | Royalty Pharma Sub-Manager, LLC | 3.6% | 2,388,150 | $47M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Bicara Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Reference
Frequently asked questions
- When is the Bicara Therapeutics Inc 2026 annual meeting?
- Bicara Therapeutics Inc (BCAX) holds its 2026 annual shareholder meeting on Tuesday, June 9, 2026.
- What is the record date for the Bicara Therapeutics Inc 2026 meeting?
- The record date for the Bicara Therapeutics Inc 2026 meeting is Wednesday, April 15, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Bicara Therapeutics Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Bicara Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Bicara Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Bicara Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.